Expert Discusses Key Findings of Longer Term Follow Up of iFCR Therapy Study for Chronic Lymphocytic Leukemia

In a Pharmacy Times® Interview, Matthew Davids, MD, MMSc, associate professor of medicine at Harvard Medical School, discusses his oral presentation at ASH 2021 of the Longer Term Follow-up of a Multicenter, Phase 2 Study of Ibrutinib Plus Fludarabine, Cyclophosphamide, Rituximab (iFCR) As Initial Therapy for Younger Patients with Chronic Lymphocytic Leukemia (CLL).

He discussed the results of a longer-term follow up for iFCR therapy for individuals with CLL.